Delivery of Cabotegravir LA Injectable pre-exposure prophylaxis (PrEP) as an HIV prevention product option within the Fast-PrEP project.

Desmond Tutu Health Foundation0 个研究点目标入组 1,800 人开始时间: 2023年2月14日最近更新: 2023年5月29日

试验速览

暂无简介。

•Aged 15-29 years
•Member of a target population: adolescent girls and young women, young key populations (young people who trade sex; young gender and sexually diverse populations), or intimate partners of these populations.
•Pregnant and breastfeeding women
•HIV negative
•Body weight >= 35 kg at baseline
•Currently residing in the study criteria
•Able to provide written, informed voluntary consent to partake in the study and willing
•Able to receive a PrEP product

•Confirmed HIV-positive test result and/or signs and symptoms of an acute HIV infection
•Weight <35kg
•Clinical conditions - pregnant women cannot use the vaginal ring; individuals with inflammatory skin conditions that could compromise the safety of an intramuscular injection.
•Allergy to any of the study products
•Use of contraindicated medications (e.g. Rifampicin should not be co-administered with CAB-LA).
•Do not spend a reasonable amount of time in the study area as residents, for school, or work, or are otherwise unable to participate in study visits for geographical reasons, according to the site investigator
•Medical, social or other condition that, in the opinion of the site investigator, would interfere with the conduct of the study or safety of the participant (e.g., provided by self-report, or found upon medical history and examination or in available medical records)

发起方

Desmond Tutu Health Foundation